Sign In
Buy ABMD
$381.02
+0 (+0%)
At Close: Mar 20, 2023
Abiomed's (ABMD) CEO Mike Minogue on Q2 2022 Results - Earnings Call Transcript
12:34pm, Thursday, 28'th Oct 2021
Abiomed's (ABMD) CEO Mike Minogue on Q2 2022 Results - Earnings Call Transcript
Abiomed (ABMD) Q2 Earnings Beat Estimates
10:43am, Thursday, 28'th Oct 2021
Abiomed (ABMD) delivered earnings and revenue surprises of 5.10% and -0.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Abiomed (ABMD) Stock Jumps 5.9%: Will It Continue to Soar?
04:54am, Wednesday, 06'th Oct 2021
Abiomed (ABMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Here's Why You Should Retain Abiomed (ABMD) Stock For Now
11:28am, Monday, 20'th Sep 2021
Investors continue to be optimistic about Abiomed (ABMD) owing to its strength in the Impella product line.
Abiomed: Impella Will Continue To Drive Revenue Growth
01:17pm, Friday, 10'th Sep 2021
Abiomed's strong growth drivers and advanced product pipeline will boost its long-term revenue growth. The company's Impella range of micro heart pumps will continue to see increasing adoption globall
Abiomed's (ABMD) Impella ECP Gets FDA's Breakthrough Device Tag
12:16pm, Thursday, 19'th Aug 2021
Abiomed's (ABMD) Impella ECP is likely to offer critical hemodynamic support to a wider pool of coronary artery disease patients.
Smallest Heart Pump From Abiomed Gets FDA Breakthrough Device Tag
11:04am, Wednesday, 18'th Aug 2021
The FDA has granted breakthrough device designation to Abiomed Inc's (NASDAQ: ABMD) Impella ECP expandable percutaneous heart pump. Abiomed designed the Impella ECP heart pump to be compatible wit
FDA Grants Breakthrough Device Designation to Impella ECP, the World's Smallest Heart Pump
08:02am, Wednesday, 18'th Aug 2021
DANVERS, Mass.--(BUSINESS WIRE)--The U.S. Food and Drug Administration has granted breakthrough device designation to Abiomed's Impella ECP expandable percutaneous heart pump.
Here's Why You Should Retain Abiomed (ABMD) Stock for Now
01:09pm, Friday, 13'th Aug 2021
Investors continue to be optimistic about Abiomed (ABMD) owing to its strength in the Impella product line.
Abiomed's (ABMD) Q1 Earnings and Revenues Beat, Margins Up
01:42pm, Thursday, 05'th Aug 2021
Abiomed's (ABMD) strength in Impella product revenues drives its Q1 top line.
Abiomed, Inc. (ABMD) CEO Mike Minogue on Q1 2022 Results - Earnings Call Transcript
01:38pm, Thursday, 05'th Aug 2021
Abiomed, Inc. (ABMD) CEO Mike Minogue on Q1 2022 Results - Earnings Call Transcript
Abiomed (ABMD) Beats Q1 Earnings and Revenue Estimates
08:35pm, Wednesday, 04'th Aug 2021
Abiomed (ABMD) delivered earnings and revenue surprises of 3.77% and 3.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Abiomed Announces Record Revenue of $253 Million, Up 53% Year Over Year
04:15pm, Wednesday, 04'th Aug 2021
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces record revenue of $253 million, up 53% year over year.
Abiomed (ABMD) Reports Next Week: Wall Street Expects Earnings Growth
04:44pm, Thursday, 29'th Jul 2021
Abiomed (ABMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abiomed: Recovery Mode Has Been Activated - Reiterate Buy Rating
10:23am, Tuesday, 13'th Jul 2021
Abiomed has commenced its path to recovery on the charts, following a big hit in April this year. Key tension points for ABMD's share price lie in its Impella sales volume, which continues to gain tra
